Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and ...

When you only buy stocks that you have strong convictions about as long-term investments (based on sound research, your ...

Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...